Neoplasms of the Kidney and Bladder

  • Edward M. Uchio
  • Juan S. Calderon
  • Jonathan J. Hwang


The vast majority of human neoplasms appear to be coupled with the biology of aging. Over 70% of all cancers will occur in individuals over the age of 65 by the year 2030 [1, 2]. The age-specific incidence of many different types of cancer begin to rise steadily as we mature, and neoplasms arising from the kidney and bladder are of no exception. Approximately 88,200 men and 40,500 women developed a malignancy of the kidney or urinary bladder in 2009 [3]. The treatment of these malignancies in the elderly population requires careful consideration of factors such as life expectancy, incidence of treatment complications, and quality of life. This chapter reviews the incidence of kidney and bladder malignancies, the appropriate evaluation in the elderly, surgical and medical treatments available to treat the geriatric patient, and the complications associated with treatment.


Bladder Cancer Partial Nephrectomy Radical Cystectomy Transitional Cell Carcinoma Renal Mass 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Edwards BK, Howe HL, Ries LA et al (2002) Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94(10):2766–2792PubMedCrossRefGoogle Scholar
  2. 2.
    Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166(5):1611–1623PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249PubMedCrossRefGoogle Scholar
  4. 4.
    Dechet CB, Sebo T, Farrow G, Blute ML, Engen DE, Zincke H (1999) Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol 162(4):1282–1284; discussion 4–5PubMedCrossRefGoogle Scholar
  5. 5.
    Nelson CP, Sanda MG (2002) Contemporary diagnosis and management of renal angiomyolipoma. J Urol 168(4 Pt 1):1315–1325PubMedGoogle Scholar
  6. 6.
    Bissler JJ, Kingswood JC (2004) Renal angiomyolipomata. Kidney Int 66(3):924–934PubMedCrossRefGoogle Scholar
  7. 7.
    Bosniak MA, Megibow AJ, Hulnick DH, Horii S, Raghavendra BN (1988) CT diagnosis of renal angiomyolipoma: the importance of detecting small amounts of fat. AJR Am J Roentgenol 151(3):497–501PubMedGoogle Scholar
  8. 8.
    Choyke PL, Glenn GM, Walther MM, Zbar B, Linehan WM (2003) Hereditary renal cancers. Radiology 226(1):33–46PubMedCrossRefGoogle Scholar
  9. 9.
    Hwang JJ, Uchio EM, Linehan WM, Walther MM (2003) Hereditary kidney cancer. Urol Clin North Am 30(4):831–842PubMedCrossRefGoogle Scholar
  10. 10.
    Dhote R, Thiounn N, Debre B, Vidal-Trecan G (2004) Risk factors for adult renal cell carcinoma. Urol Clin North Am 31(2):237–247PubMedCrossRefGoogle Scholar
  11. 11.
    Iliopoulos O, Eng C (2000) Genetic and clinical aspects of familial renal neoplasms. Semin Oncol 27(2):138–149PubMedGoogle Scholar
  12. 12.
    Maher ER, Yates JR, Harries R et al (1990) Clinical features and natural history of von Hippel–Lindau disease. Q J Med 77(283):1151–1163PubMedCrossRefGoogle Scholar
  13. 13.
    Latif F, Tory K, Gnarra J et al (1993) Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 260(5112):1317–1320PubMedCrossRefGoogle Scholar
  14. 14.
    Zambrano NR, Lubensky IA, Merino MJ, Linehan WM, Walther MM (1999) Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol 162(4):1246–1258PubMedCrossRefGoogle Scholar
  15. 15.
    Gnarra JR, Tory K, Weng Y et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7(1):85–90PubMedCrossRefGoogle Scholar
  16. 16.
    Shuin T, Kondo K, Torigoe S et al (1994) Frequent somatic mutations and loss of heterozygosity of the von Hippel–Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54(11):2852–2855PubMedGoogle Scholar
  17. 17.
    Bosniak MA (1995) Observation of small incidentally detected renal masses. Semin Urol Oncol 13(4):267–272PubMedGoogle Scholar
  18. 18.
    Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J (1995) Small renal parenchymal neoplasms: further observations on growth. Radiology 197(3):589–597PubMedGoogle Scholar
  19. 19.
    Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA (2004) The natural history of incidentally detected small renal masses. Cancer 100(4):738–745PubMedCrossRefGoogle Scholar
  20. 20.
    Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF (1971) Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28(5):1165–1177PubMedCrossRefGoogle Scholar
  21. 21.
    Thrasher JB, Paulson DF (1993) Prognostic factors in renal cancer. Urol Clin North Am 20(2):247–262PubMedGoogle Scholar
  22. 22.
    Edge SB, American Joint Committee on Cancer, American Cancer Society (2010) AJCC cancer staging handbook: from the AJCC cancer staging manual, 7th edn. Springer, New YorkGoogle Scholar
  23. 23.
    Jayson M, Sanders H (1998) Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51(2):203–205PubMedCrossRefGoogle Scholar
  24. 24.
    Ritchie AW, Chisholm GD (1983) The natural history of renal carcinoma. Semin Oncol 10(4):390–400PubMedGoogle Scholar
  25. 25.
    Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr (1999) Rising incidence of renal cell cancer in the United States. JAMA 281(17):1628–1631PubMedCrossRefGoogle Scholar
  26. 26.
    Homma Y, Kawabe K, Kitamura T et al (1995) Increased incidental detection and reduced mortality in renal cancer–recent retrospective analysis at eight institutions. Int J Urol 2(2):77–80PubMedCrossRefGoogle Scholar
  27. 27.
    Carini M, Selli C, Barbanti G, Lapini A, Turini D, Costantini A (1988) Conservative surgical treatment of renal cell carcinoma: clinical experience and reappraisal of indications. J Urol 140(4):725–731PubMedGoogle Scholar
  28. 28.
    Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2):425–431PubMedCrossRefGoogle Scholar
  29. 29.
    Abouassaly R, Lane BR, Novick AC (2008) Active surveillance of renal masses in elderly patients. J Urol 180(2):505–508; discussion 8–9PubMedCrossRefGoogle Scholar
  30. 30.
    Klatte T, Patard JJ, de Martino M et al (2008) Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol 179(5):1719–1726PubMedCrossRefGoogle Scholar
  31. 31.
    Campbell SC, Novick AC, Belldegrun A et al (2009) Guideline for management of the clinical T1 renal mass. J Urol 182(4):1271–1279PubMedCrossRefGoogle Scholar
  32. 32.
    Washburn ZW, Dillman JR, Cohan RH, Caoili EM, Ellis JH (2009) Computed tomographic urography update: an evolving urinary tract imaging modality. Semin Ultrasound CT MR 30(4):233–245PubMedCrossRefGoogle Scholar
  33. 33.
    Mulholland SG, Stefanelli JL (1990) Genitourinary cancer in the elderly. Am J Kidney Dis 16(4):324–328PubMedGoogle Scholar
  34. 34.
    Bosniak MA (1997) The use of the Bosniak classification system for renal cysts and cystic tumors. J Urol 157(5):1852–1853PubMedCrossRefGoogle Scholar
  35. 35.
    Davidson AJ, Hartman DS, Choyke PL, Wagner BJ (1997) Radiologic assessment of renal masses: implications for patient care. Radiology 202(2):297–305PubMedGoogle Scholar
  36. 36.
    Trivedi H, Raman L, Benjamin H, Batwara R (2009) Lack of nephrotoxicity of gadodiamide in unselected hospitalized patients. Postgrad Med 121(5):166–170PubMedCrossRefGoogle Scholar
  37. 37.
    Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108PubMedCrossRefGoogle Scholar
  38. 38.
    Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER III, Semelka RC (2009) Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy – report from two U.S. universities. Radiology 253(3):689–696PubMedCrossRefGoogle Scholar
  39. 39.
    Thomsen HS (2009) How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States. Radiol Clin North Am 47(5):871–875; viiPubMedCrossRefGoogle Scholar
  40. 40.
    Thomsen HS, Morcos SK, Barrett BJ (2008) Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol 49(6):646–657PubMedCrossRefGoogle Scholar
  41. 41.
    Idee JM, Port M, Dencausse A, Lancelot E, Corot C (2009) Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 47(5):855–869; viiPubMedCrossRefGoogle Scholar
  42. 42.
    Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101(3):297–301PubMedGoogle Scholar
  43. 43.
    Pantuck AJ, Zisman A, Dorey F et al (2003) Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 97(12):2995–3002PubMedCrossRefGoogle Scholar
  44. 44.
    Hellsten S, Johnsen J, Berge T, Linell F (1990) Clinically unrecognized renal cell carcinoma. Diagnostic and pathological aspects. Eur Urol 18(Suppl 2):23Google Scholar
  45. 45.
    Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P (1986) Renal cell carcinoma: survival and prognostic factors. Urology 27(4):291–301PubMedCrossRefGoogle Scholar
  46. 46.
    Giuliani L, Giberti C, Martorana G, Rovida S (1990) Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143(3):468–473; discussion 73–74PubMedGoogle Scholar
  47. 47.
    Kontak JA, Campbell SC (2003) Prognostic factors in renal cell carcinoma. Urol Clin North Am 30(3):467–480PubMedCrossRefGoogle Scholar
  48. 48.
    Ramon J, Goldwasser B, Raviv G, Jonas P, Many M (1991) Long-term results of simple and radical nephrectomy for renal cell carcinoma. Cancer 67(10):2506–2511PubMedCrossRefGoogle Scholar
  49. 49.
    Siemer S, Lehmann J, Loch A et al (2005) Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 173(1):33–37PubMedCrossRefGoogle Scholar
  50. 50.
    Thrasher JB, Crawford ED (1993) Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149(5):957–972PubMedGoogle Scholar
  51. 51.
    Haas NB, Uzzo R (2008) Adjuvant therapy for renal cell carcinoma. Curr Oncol Rep 10(3):245–252PubMedCrossRefGoogle Scholar
  52. 52.
    Clayman RV, Kavoussi LR, Soper NJ et al (1991) Laparoscopic nephrectomy: initial case report. J Urol 146(2):278–282PubMedGoogle Scholar
  53. 53.
    Meraney AM, Gill IS (2002) Financial analysis of open versus laparoscopic radical nephrectomy and nephroureterectomy. J Urol 167(4):1757–1762PubMedCrossRefGoogle Scholar
  54. 54.
    Ono Y, Hattori R, Gotoh M, Yoshino Y, Yoshikawa Y, Kamihira O (2005) Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already? Curr Opin Urol 15(2):75–78PubMedCrossRefGoogle Scholar
  55. 55.
    Portis AJ, Yan Y, Landman J et al (2002) Long-term followup after laparoscopic radical nephrectomy. J Urol 167(3):1257–1262PubMedCrossRefGoogle Scholar
  56. 56.
    Chacko JK, Koyle MA, Mingin GC, Furness PD III (2007) Minimally invasive open renal surgery. J Urol 178(4 Pt 2):1575–1577; discussion 7–8PubMedCrossRefGoogle Scholar
  57. 57.
    Eden CG, Haigh AC, Carter PG, Coptcoat MJ (1994) Laparoscopic nephrectomy results in better postoperative pulmonary function. J Endourol 8(6):419–422; discussion 22–23PubMedCrossRefGoogle Scholar
  58. 58.
    Badger WJ, Gallagher BL, Szeluga DJ, Winfield HN (2008) Hurdles to helium gas laparoscopy and a readily available alternative. J Endourol 22(11):2455–2459PubMedCrossRefGoogle Scholar
  59. 59.
    Lai FC, Kau EL, Ng CS, Fuchs GJ (2007) Laparoscopic nephrectomy outcomes of elderly patients in the 21st century. J Endourol 21(11):1309–1313PubMedCrossRefGoogle Scholar
  60. 60.
    Najarian JS, Chavers BM, McHugh LE, Matas AJ (1992) 20 years or more of follow-up of living kidney donors. Lancet 340(8823):807–810PubMedCrossRefGoogle Scholar
  61. 61.
    Goldfarb DA, Matin SF, Braun WE et al (2001) Renal outcome 25 years after donor nephrectomy. J Urol 166(6):2043–2047PubMedCrossRefGoogle Scholar
  62. 62.
    Bijol V, Mendez GP, Hurwitz S, Rennke HG, Nose V (2006) Evaluation of the nonneoplastic pathology in tumor nephrectomy specimens: predicting the risk of progressive renal failure. Am J Surg Pathol 30(5):575–584PubMedCrossRefGoogle Scholar
  63. 63.
    Huang WC, Levey AS, Serio AM et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7(9):735–740PubMedCrossRefGoogle Scholar
  64. 64.
    Castilla EA, Liou LS, Abrahams NA et al (2002) Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology 60(6):993–997PubMedCrossRefGoogle Scholar
  65. 65.
    Uzzo RG, Novick AC (2001) Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 166(1):6–18PubMedCrossRefGoogle Scholar
  66. 66.
    Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P (2000) Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol 163(3):730–736PubMedCrossRefGoogle Scholar
  67. 67.
    Stephenson AJ, Hakimi AA, Snyder ME, Russo P (2004) Complications of radical and partial nephrectomy in a large contemporary cohort. J Urol 171(1):130–134PubMedCrossRefGoogle Scholar
  68. 68.
    Thomas AA, Aron M, Hernandez AV, Lane BR, Gill IS (2009) Laparoscopic partial nephrectomy in octogenarians. Urology 74(5):1042–1046PubMedCrossRefGoogle Scholar
  69. 69.
    Michaels MJ, Rhee HK, Mourtzinos AP, Summerhayes IC, Silverman ML, Libertino JA (2002) Incomplete renal tumor destruction using radio frequency interstitial ablation. J Urol 168(6):2406–2409; discussion 9–10PubMedCrossRefGoogle Scholar
  70. 70.
    Rendon RA, Kachura JR, Sweet JM et al (2002) The uncer­tainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol 167(4):1587–1592PubMedCrossRefGoogle Scholar
  71. 71.
    Matlaga BR, Zagoria RJ, Woodruff RD, Torti FM, Hall MC (2002) Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol 168(6):2401–2405PubMedCrossRefGoogle Scholar
  72. 72.
    Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124PubMedCrossRefGoogle Scholar
  73. 73.
    Balducci L (2009) Supportive care in elderly cancer patients. Curr Opin Oncol 21(4):310–317PubMedCrossRefGoogle Scholar
  74. 74.
    Balducci L (2009) Pharmacology of antineoplastic medications in older cancer patients. Oncology (Williston Park) 23(1):78–85Google Scholar
  75. 75.
    Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22(1):42–60PubMedGoogle Scholar
  76. 76.
    Milowsky MI, Nanus DM (2003) Chemotherapeutic strategies for renal cell carcinoma. Urol Clin North Am 30(3):601–609, xPubMedCrossRefGoogle Scholar
  77. 77.
    Kroog GS, Motzer RJ (2008) Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am 35(4):687–701, ixPubMedCrossRefGoogle Scholar
  78. 78.
    Dutcher JP, Fisher RI, Weiss G et al (1997) Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 3(3):157–162PubMedGoogle Scholar
  79. 79.
    Negrier S, Escudier B, Lasset C et al (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 338(18):1272–1278PubMedCrossRefGoogle Scholar
  80. 80.
    Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21(16):3127–3132PubMedCrossRefGoogle Scholar
  81. 81.
    Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281PubMedCrossRefGoogle Scholar
  82. 82.
    Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134PubMedCrossRefGoogle Scholar
  83. 83.
    Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456PubMedCrossRefGoogle Scholar
  84. 84.
    Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763PubMedCrossRefGoogle Scholar
  85. 85.
    Schultzel M, Saltzstein SL, Downs TM, Shimasaki S, Sanders C, Sadler GR (2008) Late age (85 years or older) peak incidence of bladder cancer. J Urol 179(4):1302–1305; discussion 5–6PubMedCrossRefGoogle Scholar
  86. 86.
    Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK (2005) Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer 104(8):1638–1647PubMedCrossRefGoogle Scholar
  87. 87.
    Konety BR, Joslyn SA (2003) Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 170(5):1765–1771PubMedCrossRefGoogle Scholar
  88. 88.
    Briggs NC, Young TB, Gilchrist KW, Vaillancourt AM, Messing EM (1992) Age as a predictor of an aggressive clinical course for superficial bladder cancer in men. Cancer 69(6):1445–1451PubMedCrossRefGoogle Scholar
  89. 89.
    Mariani AJ, Mariani MC, Macchioni C, Stams UK, Hariharan A, Moriera A (1989) The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 141(2):350–355PubMedGoogle Scholar
  90. 90.
    Britton JP, Dowell AC, Whelan P, Harris CM (1992) A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 148(3):788–790PubMedGoogle Scholar
  91. 91.
    Vikram R, Sandler CM, Ng CS (2009) Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract. AJR Am J Roentgenol 192(6):1481–1487PubMedCrossRefGoogle Scholar
  92. 92.
    Sidransky D, Von Eschenbach A, Tsai YC et al (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252(5006):706–709PubMedCrossRefGoogle Scholar
  93. 93.
    Feng Z, Hu W, Teresky AK, Hernando E, Cordon-Cardo C, Levine AJ (2007) Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A 104(42):16633–16638PubMedCrossRefGoogle Scholar
  94. 94.
    Stuart GR, Oda Y, de Boer JG, Glickman BW (2000) Mutation frequency and specificity with age in liver, bladder and brain of lacI transgenic mice. Genetics 154(3):1291–1300PubMedGoogle Scholar
  95. 95.
    Taylor JA 3rd, Kuchel GA (2009) Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol 6(3):135–144PubMedCrossRefGoogle Scholar
  96. 96.
    Bornman DM, Mathew S, Alsruhe J, Herman JG, Gabrielson E (2001) Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol 159(3):831–835PubMedCrossRefGoogle Scholar
  97. 97.
    Habuchi T, Takahashi T, Kakinuma H et al (2001) Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 20(4):531–537PubMedCrossRefGoogle Scholar
  98. 98.
    Gu J, Spitz MR, Zhao H et al (2005) Roles of tumor suppressor and telomere maintenance genes in cancer and aging–an epidemiological study. Carcinogenesis 26(10):1741–1747PubMedCrossRefGoogle Scholar
  99. 99.
    Koch M, Hill GB, McPhee MS (1986) Factors affecting recurrence rates in superficial bladder cancer. J Natl Cancer Inst 76(6):1025–1029PubMedGoogle Scholar
  100. 100.
    Cooksley CD, Avritscher EB, Grossman HB et al (2008) Clinical model of cost of bladder cancer in the elderly. Urology 71(3):519–525PubMedCrossRefGoogle Scholar
  101. 101.
    Ro JY, Staerkel GA, Ayala AG (1992) Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 19(3):435–453PubMedGoogle Scholar
  102. 102.
    Fitzpatrick JM, West AB, Butler MR, Lane V, O’Flynn JD (1986) Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 135(5):920–922PubMedGoogle Scholar
  103. 103.
    Torti FM, Lum BL, Aston D et al (1987) Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol 5(1):125–130PubMedGoogle Scholar
  104. 104.
    Heney NM, Ahmed S, Flanagan MJ et al (1983) Superficial bladder cancer: progression and recurrence. J Urol 130(6):1083–1086PubMedGoogle Scholar
  105. 105.
    Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM (1993) Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150(1):60–64PubMedGoogle Scholar
  106. 106.
    Allard P, Bernard P, Fradet Y, Tetu B (1998) The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 81(5):692–698PubMedCrossRefGoogle Scholar
  107. 107.
    Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164(3 Pt 1):680–684PubMedCrossRefGoogle Scholar
  108. 108.
    Holmang S, Hedelin H, Anderstrom C, Johansson SL (1995) The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153(6):1823–1826; discussion 6–7PubMedCrossRefGoogle Scholar
  109. 109.
    Pagano F, Garbeglio A, Milani C, Bassi P, Pegoraro V (1987) Prognosis of bladder cancer I. Risk factors in superficial transitional cell carcinoma. Eur Urol 13(3):145–149PubMedGoogle Scholar
  110. 110.
    Althausen AF, Prout GR Jr, Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116(5):575–580PubMedGoogle Scholar
  111. 111.
    Wallace DM, Hindmarsh JR, Webb JN et al (1979) The role of multiple mucosal biopsies in the management of patients with bladder cancer. Br J Urol 51(6):535–540PubMedCrossRefGoogle Scholar
  112. 112.
    Farrow GM, Utz DC, Rife CC, Greene LF (1977) Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 37(8 Pt 2):2794–2798PubMedGoogle Scholar
  113. 113.
    Bostwick DG (1992) Natural history of early bladder cancer. J Cell Biochem Suppl 16I:31–38PubMedCrossRefGoogle Scholar
  114. 114.
    Prout GR Jr, Griffin PP, Daly JJ (1987) The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 138(4):766–770PubMedGoogle Scholar
  115. 115.
    Witjes JA, Mungan NA, Debruyne FM (2000) Management of superficial bladder cancer with intravesical chemotherapy: an update. Urology 56(1):19–21PubMedCrossRefGoogle Scholar
  116. 116.
    Peyromaure M, Zerbib M (2004) T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 93(1):60–63PubMedCrossRefGoogle Scholar
  117. 117.
    Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167(4):1573–1583PubMedCrossRefGoogle Scholar
  118. 118.
    Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 162(5):1697–1701PubMedCrossRefGoogle Scholar
  119. 119.
    Sylvester RJ, der MA Van, Lamm DL (2002) Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964–1970PubMedCrossRefGoogle Scholar
  120. 120.
    Cookson MS, Sarosdy MF (1992) Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette–Guerin therapy. J Urol 148(3):797–801PubMedGoogle Scholar
  121. 121.
    Bohle A, Bock PR (2004) Intravesical bacille Calmette–Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63(4):682–686; discussion 6–7PubMedCrossRefGoogle Scholar
  122. 122.
    Herr HW (1997) High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumor. Semin Urol Oncol 15(3):142–146PubMedGoogle Scholar
  123. 123.
    Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B (2003) The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 43(3):241–245PubMedCrossRefGoogle Scholar
  124. 124.
    Herr HW (1997) Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 80(5):762–765PubMedCrossRefGoogle Scholar
  125. 125.
    Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C (2002) Guidelines on bladder cancer. Eur Urol 41(2):105–112PubMedCrossRefGoogle Scholar
  126. 126.
    Esrig D, Freeman JA, Stein JP, Skinner DG (1997) Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol 15(3):154–160PubMedGoogle Scholar
  127. 127.
    Barlow LJ, McKiernan JM, Benson MC (2009) The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 27(3):331–335PubMedCrossRefGoogle Scholar
  128. 128.
    Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L Jr et al (1990) Bacillus Calmette–Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 143(3):502–506PubMedGoogle Scholar
  129. 129.
    Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K (2005) Bacillus Calmette–Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a ­meta-analysis of the published results of randomized clinical trials. J Urol 174(1):86–91; discussion 2PubMedCrossRefGoogle Scholar
  130. 130.
    Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M (2003) Intravesical Bacillus Calmette–Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev (3):CD003231Google Scholar
  131. 131.
    Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M (2000) Intravesical Bacillus Calmette–Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev (4):CD001986Google Scholar
  132. 132.
    Lamm DL (1991) Comparison of BCG with other intravesical agents. Urology 37(5 Suppl):30–32PubMedCrossRefGoogle Scholar
  133. 133.
    Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette–Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124–1129PubMedCrossRefGoogle Scholar
  134. 134.
    Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al (2005) Has a 3-fold decreased dose of bacillus Calmette–Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174(4 Pt 1):1242–1247PubMedCrossRefGoogle Scholar
  135. 135.
    Herr HW (2007) Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology 70(1):65–68PubMedCrossRefGoogle Scholar
  136. 136.
    Droller MJ (1992) Treatment of regionally advanced bladder cancer. An overview. Urol Clin North Am 19(4):685–693PubMedGoogle Scholar
  137. 137.
    Silverman DT, Hartge P, Morrison AS, Devesa SS (1992) Epidemiology of bladder cancer. Hematol Oncol Clin North Am 6(1):1–30PubMedGoogle Scholar
  138. 138.
    Tekes A, Kamel I, Imam K et al (2005) Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol 184(1):121–127PubMedGoogle Scholar
  139. 139.
    Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H (1994) Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 193(1):239–245PubMedGoogle Scholar
  140. 140.
    Tanimoto A, Yuasa Y, Imai Y et al (1992) Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT. Radiology 185(3):741–747PubMedGoogle Scholar
  141. 141.
    Herr HW (2001) Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19(1):89–93PubMedGoogle Scholar
  142. 142.
    Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB (2003) Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95(8):588–597PubMedCrossRefGoogle Scholar
  143. 143.
    Skinner DG, Lieskovsky G (1984) Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 131(6):1069–1072PubMedGoogle Scholar
  144. 144.
    Reisinger SA, Mohiuddin M, Mulholland SG (1992) Combined pre- and postoperative adjuvant radiation therapy for bladder ­cancer–a ten year experience. Int J Radiat Oncol Biol Phys 24(3):463–468PubMedCrossRefGoogle Scholar
  145. 145.
    Wammack R, Wricke C, Hohenfellner R (2002) Long-term results of ileocecal continent urinary diversion in patients treated with and without previous pelvic irradiation. J Urol 167(5):2058–2062PubMedCrossRefGoogle Scholar
  146. 146.
    Chamie K, Hu B, Devere White RW, Ellison LM (2008) Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? BJU Int 3:284–290CrossRefGoogle Scholar
  147. 147.
    Nielsen ME, Shariat SF, Karakiewicz PI et al (2007) Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 51(3):699–706; discussion 8PubMedCrossRefGoogle Scholar
  148. 148.
    Weizer AZ, Joshi D, Daignault S et al (2007) Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol 177(4):1287–1293PubMedCrossRefGoogle Scholar
  149. 149.
    Stroumbakis N, Herr HW, Cookson MS, Fair WR (1997) Radical cystectomy in the octogenarian. J Urol 158(6):2113–2117PubMedCrossRefGoogle Scholar
  150. 150.
    Roehrborn CG, Sagalowsky AI, Peters PC (1991) Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146(1):36–39PubMedGoogle Scholar
  151. 151.
    Leissner J, Ghoneim MA, Abol-Enein H et al (2004) Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 171(1):139–144PubMedCrossRefGoogle Scholar
  152. 152.
    Smith AB, Nielsen ME, Wallen EM, Pruthi RS. Current status of robot-assisted radical cystectomy. Curr Opin Urol. 2009 Oct 28Google Scholar
  153. 153.
    Pruthi RS, Smith A, Wallen EM (2008) Evaluating the learning curve for robot-assisted laparoscopic radical cystectomy. J Endourol 22(11):2469–2474PubMedCrossRefGoogle Scholar
  154. 154.
    Sternberg CN (1995) The treatment of advanced bladder cancer. Ann Oncol 6(2):113–126PubMedGoogle Scholar
  155. 155.
    Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10(7):1066–1073PubMedGoogle Scholar
  156. 156.
    Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8(6):1050–1055PubMedGoogle Scholar
  157. 157.
    Harker WG, Meyers FJ, Freiha FS et al (1985) Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3(11):1463–1470PubMedGoogle Scholar
  158. 158.
    Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15(12):3441–3445PubMedGoogle Scholar
  159. 159.
    Bamias A, Efstathiou E, Moulopoulos LA et al (2005) The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 16(2):307–313PubMedCrossRefGoogle Scholar
  160. 160.
    Castagneto B, Zai S, Marenco D et al (2004) Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology 67(1):27–32PubMedCrossRefGoogle Scholar
  161. 161.
    Linardou H, Aravantinos G, Efstathiou E et al (2004) Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 64(3):479–484PubMedCrossRefGoogle Scholar
  162. 162.
    Bamias A, Lainakis G, Kastritis E et al (2007) Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. Oncology 73(5–6):290–297PubMedCrossRefGoogle Scholar
  163. 163.
    Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859–866PubMedCrossRefGoogle Scholar
  164. 164.
    Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E (1996) Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic cystectomy trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 155(6):1903–1906PubMedCrossRefGoogle Scholar
  165. 165.
    Salminen E (1990) Recurrence and treatment of urinary bladder cancer after failure in radiotherapy. Cancer 66(11):2341–2345PubMedCrossRefGoogle Scholar
  166. 166.
    Given RW, Parsons JT, McCarley D, Wajsman Z (1995) Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology 46(4):499–504; discussion 5PubMedCrossRefGoogle Scholar
  167. 167.
    Brennan P, Bogillot O, Cordier S et al (2000) Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 86(2):289–294PubMedCrossRefGoogle Scholar
  168. 168.
    Morrison AS, Buring JE, Verhoek WG et al (1984) An international study of smoking and bladder cancer. J Urol 131(4):650–654PubMedGoogle Scholar
  169. 169.
    Piper JM, Tonascia J, Matanoski GM (1985) Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 313(5):292–295PubMedCrossRefGoogle Scholar
  170. 170.
    Fortuny J, Kogevinas M, Zens MS et al (2007) Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol 7:13PubMedCrossRefGoogle Scholar
  171. 171.
    Porpaczy P, Schramek P (1981) Analgesic nephropathy and phenacetin-induced transitional cell carcinoma - analysis of 300 patients with long-term consumption of phenacetin-containing drugs. Eur Urol 7(6):349–354PubMedGoogle Scholar
  172. 172.
    Cole P, Hoover R, Friedell GH (1972) Occupation and cancer of the lower urinary tract. Cancer 29(5):1250–1260PubMedCrossRefGoogle Scholar
  173. 173.
    Case RA, Pearson JT (1954) Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. II. Further consideration of the role of aniline and of the manufacture of auramine and magenta (fuchsine) as possible causative agents. Br J Ind Med 11(3):213–216PubMedGoogle Scholar
  174. 174.
    Gaertner RR, Trpeski L, Johnson KC (2004) A case-control study of occupational risk factors for bladder cancer in Canada. Cancer Causes Control 15(10):1007–1019PubMedCrossRefGoogle Scholar
  175. 175.
    Travis LB, Curtis RE, Glimelius B et al (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst 87(7):524–530PubMedCrossRefGoogle Scholar
  176. 176.
    O’Keane JC (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide. N Engl J Med 319(13):871PubMedGoogle Scholar
  177. 177.
    Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M (2005) Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 174(1):107–110; ­discussion 10–11PubMedCrossRefGoogle Scholar
  178. 178.
    Sella A, Dexeus FH, Chong C, Ro JY, Logothetis CJ (1989) Radiation therapy-associated invasive bladder tumors. Urology 33(3):185–188PubMedCrossRefGoogle Scholar
  179. 179.
    Delnay KM, Stonehill WH, Goldman H, Jukkola AF, Dmochowski RR (1999) Bladder histological changes associated with chronic indwelling urinary catheter. J Urol 161(4):1106–1108; discussion 8–9PubMedCrossRefGoogle Scholar
  180. 180.
    Michaud DS (2007) Chronic inflammation and bladder cancer. Urol Oncol 25(3):260–268PubMedCrossRefGoogle Scholar
  181. 181.
    Sala M, Cordier S, Chang-Claude J et al (2000) Coffee consumption and bladder cancer in nonsmokers: a pooled analysis of case-control studies in European countries. Cancer Causes Control 11(10):925–931PubMedCrossRefGoogle Scholar
  182. 182.
    Zeegers MP, Dorant E, Goldbohm RA, van den Brandt PA (2001) Are coffee, tea, and total fluid consumption associated with bladder cancer risk? Results from the Netherlands Cohort Study. Cancer Causes Control 12(3):231–238PubMedCrossRefGoogle Scholar
  183. 183.
    Takkouche B, Etminan M, Montes-Martinez A (2005) Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA 293(20):2516–2525PubMedCrossRefGoogle Scholar
  184. 184.
    Sontag JM (1980) Experimental identification of genitourinary carcinogens. Urol Clin North Am 7(3):803–814PubMedGoogle Scholar
  185. 185.
    Villanueva CM, Fernandez F, Malats N, Grimalt JO, Kogevinas M (2003) Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health 57(3):166–173PubMedCrossRefGoogle Scholar
  186. 186.
    Marshall G, Ferreccio C, Yuan Y et al (2007) Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 99(12):920–928PubMedCrossRefGoogle Scholar
  187. 187.
    Kurth KH, Denis L, Bouffioux C et al (1995) Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 31A(11):1840–1846PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Edward M. Uchio
    • 1
  • Juan S. Calderon
  • Jonathan J. Hwang
  1. 1.Yale University School of MedicineNew HavenUSA

Personalised recommendations